Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06294236 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
A Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus), sponsored by Sana Biotechnology.
- Active
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 5
- Study locations
NCT06294236 is a Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus) that is active but no longer recruiting, run by Sana Biotechnology. The registered enrollment target is 7 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06294236, a Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus), is active but no longer recruiting, sponsored by Sana Biotechnology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 5
- Study locations
Study Summary
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
Conditions Studied
Interventions
- BIOLOGICAL SC291
Study Locations (5)
Colorado
- University of Colorado - Aurora
Georgia
- Emory University - Atlanta
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Washington
- Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06294236
The ClinicalTrials.gov registry entry for NCT06294236 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (98% lower). The listed sponsor is Sana Biotechnology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which SC291 is the first listed.
NCT06294236 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Georgia, Maryland.
Frequently Asked Questions
What is clinical trial NCT06294236 about?
NCT06294236 is a clinical study titled "Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)". SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
What is the current status of trial NCT06294236?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2024-04-29. Estimated completion is 2028-03.
What conditions does trial NCT06294236 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, SLE (Systemic Lupus), Microscopic Polyangiitis, Lupus Erythematosus, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
What interventions are being tested in trial NCT06294236?
The interventions under investigation include: SC291 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06294236?
This trial is sponsored by Sana Biotechnology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06294236 being conducted?
This trial has 5 study locations across Colorado, Georgia, Maryland, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.